Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

Cellular Oncology

Volumn 38, Issue 2, 2015, Pages 131-144

  Maier, Armin ^a   Peille, Anne Lise ^a   Vuaroqueaux, Vincent ^a   Lahn, Michael ^b,c  

^a CHARLES RIVER LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NONE   (United States)

Author keywords

Anti tumor activity; Galunisertib; Gene expression; Patient derived xenografts; TGF

Indexed keywords

ANTINEOPLASTIC AGENT; LY-2157299; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CHILD; DRUG SCREENING; FEMALE; HUMAN; MALE; MIDDLE AGED; MOUSE; NEOPLASMS, EXPERIMENTAL; PROCEDURES; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHILD; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; PYRAZOLES; QUINOLINES; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84939960795     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0210-8     Document Type: Article

References (42)

1. A.B. Roberts, M.A. Anzano, L.C. Lamb, J.M. Smith, M.B. Sporn, New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc. Natl. Acad. Sci. U. S. A. 78, 5339–5343 (1981)
2. R.J. Akhurst, A. Hata, Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 11, 790–811 (2012)
3. C.H. Heldin, A. Moustakas, Role of Smads in TGFβ signaling. Cell Tissue Res. 347, 21–36 (2012)
4. R. Derynck, Y.E. Zhang, Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577–584 (2003)
5. M. Lahn, S. Kloeker, B.S. Berry, TGF-beta inhibitors for the treatment of cancer. Expert Opin. Investig. Drugs 14, 629–643 (2005)
6. J.S. Sawyer, D.W. Beight, K.S. Britt, B.D. Anderson, R.M. Campbell, T. Goodson Jr., D.K. Herron, H.Y. Li, W.T. McMillen, N. Mort, S. Parsons, E.C. Smith, J.R. Wagner, L. Yan, F. Zhang, J.M. Yingling, Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg. Med. Chem. Lett. 14, 3581–3584 (2004)
7. F. Dituri, A. Mazzocca, F.J. Peidro, P. Papappicco, I. Fabregat, F. De Santis, A. Paradiso, C. Sabba, G. Giannelli, Differential inhibition of the TGF-β signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-β receptor type II. PLoS ONE 8, e67109 (2013)
8. J. Rodon, M.A. Carducci, J.M. Sepúlveda, A. Azaro, E. Calvo, J. Seoane, I. Brana, E. Sicart, I. Gueorguieva, A. Cleverly, S. Pillay, D. Desaiah, M.M.F. Lahn, L. Paz-Ares, M. Holdhoff, J.O.N. Blakeley, J. Baselga, First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin. Canc. Res. In Press (2014)
9. S.J. Faivre, A. Santoro, R.K. Kelley, P. Merle, E. Gane, J.-Y. Douillard, D. Waldschmidt, M.F. Mulcahy, C. Costentin, B. Minguez, P. Papappicco, I. Gueorguieva, A. Cleverly, D. Desaiah, M.M.F. Lahn, N. Murray, K.A. Benhadji, E. Raymond, G. Giannelli, Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC). ASCO Gastrointestinal Cancers Symposium, (2014)
10. S. Parsons, S. Sawyer, L. Yan, R. Foreman, S. Weir, M.M.F. Lahn, J. Yingling and J.R. Graff, The combination of the small molecule TGFβR1 inhibitor LY2157299 monohydrate with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth. Abstract C201. Poster Presentation. Molecular Cancer Therapeutics: November 2011; Volume 10, Issue 11, Supplement 1. doi: 10.1158/1535-7163.TARG-11-C201; San Francisco, CA. Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12–16, (2011)
11. E.C. Connolly, E.F. Saunier, D. Quigley, M.T. Luu, A. De Sapio, B. Hann, J.M. Yingling, R.J. Akhurst, Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res. 71, 2339–2349 (2011)
12. D.P. Berger, H. Henss, B.R. Winterhalter, H.H. Fiebig, The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening. Ann. Oncol. 1, 333–341 (1990)
13. H.H. Fiebig, in In Immunodeficient mice in oncology, ed. By D. P. Berger (S Karger, Basel, 1992), p. 321–351
14. S. Julien, A. Merino-Trigo, L. Lacroix, M. Pocard, D. Goere, P. Mariani, S. Landron, L. Bigot, F. Nemati, P. Dartigues, L.B. Weiswald, D. Lantuas, L. Morgand, E. Pham, P. Gonin, V. Dangles-Marie, B. Job, P. Dessen, A. Bruno, A. Pierre, H. De The, H. Soliman, M. Nunes, G. Lardier, L. Calvet, B. Demers, G. Prevost, P. Vrignaud, S. Roman-Roman, O. Duchamp, C. Berthet, Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18, 5314–5328 (2012)
15. S. Kopetz, R. Lemos, G. Powis, The promise of patient-derived xenografts: the best laid plans of mice and men. Clin. Cancer Res. 18, 5160–5162 (2012)
16. D.D. von Hoff, Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development. Cancer Metastasis Rev. 7, 357–371 (1988)
17. R. Krumbach, J. Schuler, M. Hofmann, T. Giesemann, H.H. Fiebig, T. Beckers, Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur. J. Cancer 47, 1231–1243 (2011)
18. H.H. Fiebig, V. Vuaroqueaux, A. Korrat, F. Foucault, T. Beckers, Predictive gene signatures for bevacizumab and cetuximab as well as cytotoxic agents. Int. J. Clin. Pharmacol. Ther. 50, 70–71 (2012)
19. M. Singh, N. Ferrara, Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat. Biotechnol. 30, 648–657 (2012)
20. C.C. Scholz, D.P. Berger, B.R. Winterhalter, H. Henss, H.H. Fiebig, Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur. J. Cancer 26, 901–905 (1990)
21. H.H. Fiebig, A. Maier, A.M. Burger, Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 40, 802–820 (2004)
22. H.H. Fiebig, W.A. Dengler and T. Roth. Human tumor xenografts: predictivity, characterization and discovery of new anticancer agents. In Relevance of tumor models for anticancer drug development., ed. By H.H. Fiebig and A. M. Burger (S. Karger, Basel, 1999), p. 29–50
23. A.W. Hamburger, S.E. Salmon, Primary bioassay of human tumor stem cells. Science 197, 461–463 (1977)
24. M.C. Alley, C.B. Uhl, M.M. Lieber, Improved detection of drug cytotoxicity in the soft agar colony formation assay through use of a metabolizable tetrazolium salt. Life Sci. 31, 3071–3078 (1982)
25. Q. Li, N.J. Birkbak, B. Gyorffy, Z. Szallasi, A.C. Eklund, Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinforma. 12, 474 (2011)
26. C.D. Greenman, G. Bignell, A. Butler, S. Edkins, J. Hinton, D. Beare, S. Swamy, T. Santarius, L. Chen, S. Widaa, P.A. Futreal, M.R. Stratton, PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 11, 164–175 (2010)
27. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83, 757 (1991)
28. R.H. Shoemaker, The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813 (2006)
29. Maier A, Metz T, Krumbach R, Fiebig HH, Beckers T, In vitro profiling of kinase inhibitors and targeted anticancer agents in panels of patient-derived xenografts using a clonogenic assay. Proc. Am. Assoc. Cancer Res. 52, abstract 3528 (2011)
30. L.A. Liotta, R. Mandler, G. Murano, D.A. Katz, R.K. Gordon, P.K. Chiang, E. Schiffmann, Tumor cell autocrine motility factor. Proc. Natl. Acad. Sci. U. S. A. 83, 3302–3306 (1986)
31. U. Rodeck, T. Nishiyama, A. Mauviel, Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res. 59, 547–550 (1999)
32. K. Krasagakis, C. Garbe, P.I. Schrier, C.E. Orfanos, Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res. 14, 2565–2571 (1994)
33. S. Huang, M. Holzel, T. Knijnenburg, A. Schlicker, P. Roepman, U. McDermott, M. Garnett, W. Grernrum, C. Sun, A. Prahallad, F.H. Groenendijk, L. Mittempergher, W. Nijkamp, J. Neefjes, R. Salazar, P. Ten Dijke, H. Uramoto, F. Tanaka, R.L. Beijersbergen, L.F. Wessels, R. Bernards, MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 151, 937–950 (2012)
34. H.Y. Li, Y. Wang, L. Yan, R.M. Campbell, B.D. Anderson, J.R. Wagner, J.M. Yingling, Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines. Bioorg. Med. Chem. Lett. 14, 3585–3588 (2004)
35. ™, San Diego, California, Oxford University Press (2006), p 59, Abstract # 290 (2006)
36. M.J. Anderton, H.R. Mellor, A. Bell, C. Sadler, M. Pass, S. Powell, S.J. Steele, R.R. Roberts, A. Heier, Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916–924 (2011)
37. E. Fransvea, U. Angelotti, S. Antonaci, G. Giannelli, Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47, 1557–1566 (2008)
38. E. Fransvea, A. Mazzocca, S. Antonaci, G. Giannelli, Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 49, 839–850 (2009)
39. M. Serova, D. Garbay, M.E. Riveiro, I. Bieche, M. Bouattour, E. Raymond and S. Faivre. Targeting of TGF-beta signaling results in decreased motility and invasion in parental and mulitkinase inhibitor-insensitive hepatocacinoma cells. ILCA Annual Conference, Brussels, International Liver Cancer Association (ILCA) (2011)
40. Z. Zhong, K.D. Carroll, D. Policarpio, C. Osborn, M. Gregory, R. Bassi, X. Jimenez, M. Prewett, G. Liebisch, K. Persaud, D. Burtrum, S. Wang, D. Surguladze, S. Ng, H. Griffith, P. Balderes, J. Doody, J.D. Schwartz, H. Youssoufian, E.K. Rowinsky, D.L. Ludwig, L. Witte, Z. Zhu, Y. Wu, Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells Clin. Cancer Res. 16, 1191–1205 (2010)
41. M.D. Hale, J.D. Hayden, H.I. Grabsch, Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cell. Oncol. 36, 95–112 (2013)
42. A. Geurts van Kessel, The cancer genome: from structure to function. Cell. Oncol. 37, 55–165 (2014)